Category: Medicare
-

The 2027 Medicare plan ratings will not carry the health-equity bonus CMS had planned to award.
Every Medicare Advantage and Part D plan gets a public quality score each year, from one to five stars, and that score does more than help shoppers compare options. It also decides how much extra federal money a plan collects. Federal regulators had spent several years developing a new piece of that scoring formula meant…
-

Medicare’s 2027 plan prices do not reach the public comparison tool until sometime in October.
Every fall, headlines announce the average Medicare Advantage or Part D premium for the coming year, usually sometime in September. It’s easy to assume that means you can go online that same week and see exactly what your own 2027 plan options will cost. You can’t. The number that makes headlines in September is a…
-

Insurers told the government in June which Medicare Advantage plans they would not renew, and members hear in October
Long before any Medicare Advantage member gets a letter about their plan disappearing, the insurer running that plan has already told the federal government its decision. Federal regulation requires a Medicare Advantage organization to notify the Centers for Medicare & Medicaid Services in writing by the first Monday in June if it won’t renew its…
-

About 2.28 million people on Medicare filled Ozempic, Rybelsus or Wegovy in one year, costing plans $15.16 billion
No drug on Medicare’s newly negotiated price list cost the program more in 2024 than the trio of Ozempic, Rybelsus and Wegovy. All three are versions of the same active ingredient, semaglutide, sold by Novo Nordisk under different brand names for different uses. Together they were dispensed to about 2.28 million people with Medicare Part…
-

The 85 percent cut on the diabetes pill Janumet works out to $80 a month, down from $526
Of the 15 drugs Medicare negotiated new prices for in its second round of talks, none got a bigger percentage discount than Janumet. Merck has agreed to sell the diabetes pill to Medicare drug plans for $80 for a 30-day supply starting January 1, 2027, down from a $526 list price in 2024. That’s an…
-

The negotiated Medicare price for the bowel drug Linzess is $136 a month, against a $539 list price
Linzess is not a specialty cancer drug or a rare-disease treatment. It’s a capsule millions of Americans with chronic constipation or irritable bowel syndrome take every day, and it’s now one of the 15 drugs Medicare has negotiated a lower price for. Starting January 1, 2027, a Medicare drug plan will pay AbbVie $136 for…
-

A month of the prostate cancer drug Xtandi will cost a Medicare drug plan $7,004 in January instead of $13,480
Astellas Pharma has agreed to sell Xtandi, one of the most widely used prostate cancer drugs on the market, to Medicare drug plans for $7,004 for a 30-day supply starting in January 2027. That’s down from the $13,480 the same supply cost at list price in 2024, a discount of 48 percent. The new number…
-

The fifteen drugs Medicare negotiated for next year will cost it 44 percent less, a difference of about $12 billion
Medicare has finished bargaining over the price of 15 widely used prescription drugs, and the government now has a number to show for it. If the newly agreed-upon prices had applied during 2024, Medicare would have spent an estimated $12 billion less on those drugs, a 44 percent cut in net spending. The prices themselves…
-

The letter telling a member their Medicare Advantage plan is ending has to arrive at least 90 days before it does
A federal rule most people never hear about until it affects them sets a hard floor on how much warning a Medicare Advantage member gets before their plan disappears. If an insurer decides not to renew its Medicare Advantage contract for the coming year, it cannot simply drop enrollees with a short heads-up. The notice…
-

Insurers actually paid $6.5 million of the $1.3 billion a shell equipment company billed Medicare
Prosecutors say a Pennsylvania medical-equipment company submitted at least $1.3 billion in fraudulent claims to Medicare and other insurers over five months in 2025, but the money that actually left those insurers’ accounts was a fraction of that: about $6.5 million. The gap between the number in the indictment and the number that got paid…
